Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Oct 28, 2010

Premium

Pfizer has named Paul Burke as the CTO of its oligonucleotide therapeutics unit.

Burke joins Pfizer from Merck, where he served as executive director of RNA therapeutics. Before that, he was an executive director at Amgen. He holds a PhD in chemistry from the Massachusetts Institute of Technology.

He replaces C. Satishchandran, who left Pfizer to become director of the Center for Biopharmaceutical Research and Production at North Dakota State University, Fargo.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.